Loading clinical trials...

RECRUITINGNA

Effect of a Health Pathway for People With Persistent Symptoms Covid-19

NCT05787366•Centre Hospitalier Universitaire de Saint Etienne

Summary

People with persistent symptoms of covid-19 have increased needs for needs for management of their overall health (physical, psychological and social). Persistent covid-19 symptoms have a negative impact on quality of life. By proposing a follow-up and an intervention on the reduction of these symptoms, the symptoms, the study will improve quality of life.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Persons who have been infected with Covid-19.
•Person with persistent clinical signs of Covid-19 for more than 12 weeks, referred by one of the partner structures of the project. The persistent signs of Covid-19 are: fatigue which can be severe, neurological disorders neurological disorders (cognitive, sensory, headaches), cardio-thoracic disorders (pain and chest tightness, tachycardia, dyspnea, cough) and disorders of smell and taste. Pain, digestive disorders and skin disorders are also common.
•Person who has agreed to participate and has given informed consent to participate in the study

Exclusion Criteria

•Refused to participate in the study
•Person under legal protection
•Person with severe cognitive impairment

Locations (3)

Urps Medecins Libéraux Auvergne-Rhône-Alpes

Lyon, France

Chu Saint-Etienne

Saint-Etienne, France

DAC Loire

Saint-Etienne, France

Key Dates

Start Date

November 15, 2023

Primary Completion Date

April 1, 2026

Completion Date

October 1, 2026

Last Updated

April 29, 2025

Enrollment

400

ESTIMATED participants

Conditions

COVID-19

Interventions

usual care and follow-up by a nurse

OTHER

Personalized Multifactorial Intervention (IMP)

OTHER

Contacts

Caroline DUPRE, PhD

CONTACT

0477816352 caroline.dupre@univ-st-etienne.fr

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

RECRUITINGNA

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of a Health Pathway for People With Persistent Symptoms Covid-19

Inclusion Criteria

Exclusion Criteria

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate

Positron Emission Tomography (PET) Imaging of Thrombosis